Search PubMed⌕ Search

Biomedical subjects

M Morris

Publications and source records attributed to M Morris.

At least 505 records · Page 28Linked to original sources
PubMedDate not supplied

The aftermath of suicide.

This article discusses the aftermath of a suicide. It describes the patient who died and discusses the review that followed the suicide. Many of the issues raised are relevant to both community-based and hospital-based care.

Adult↗
PubMedDate not supplied

Felbamate metabolism in pediatric and adult beagle dogs.

In a metabolism study, three male and three female pediatric dogs and three male and three female adult beagle dogs received a single oral dose of 60 mg/kg [14C]felbamate. Urine and feces were collected up to 72 hr. Excreta samples were extracted with ethyl acetate and 14C metabolite profiles were generated by HPLC analysis of the extracts. The total 14C dose recoveries were 88.2% for the pediatric and 85.9% for the adult groups; recovery in urine accounted for 61.7 and 69.7%, respectively. The 14C metabolite profiles in urine and feces were similar, with three major peaks corresponding to unchanged felbamate and two hydroxylated metabolites. There was no significant sex difference in profiles within each age group. However, the sum amount of all metabolites in the urine was higher, and the amount of unchanged drug was lower in pediatric dogs. For the 0-24 hr samples, the metabolites/drug ratio in urine was 2.0-2.1 for pediatric dogs and 1.0-1.2 for adult dogs. This indicated a higher metabolic rate in the pediatric dogs.

Administration, Oral↗
PubMedDate not supplied

T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production.

We investigated the humoral and cellular responses of ovarian cancer patients treated with viral oncolysates (VO) tumor vaccines. All patients treated with VO developed tumor cell surface-reacting antibodies and anti-hemagglutinin antibodies. Furthermore, PBMC from these patients developed cellular proliferative responses to the cellular oncolysates (CO). The in vitro proliferating population consisted mainly of CD4+ cells, as demonstrated by depletion experiments using the corresponding monoclonal antibodies and complement and by examination of the phenotype of the cells stimulated in culture with VO or cellular oncolysates. Furthermore, in the patients treated with VO we observed an increased helper activity to immunoglobulin production by PBMC collected post-VO treatment in the PWM-driven differentiation system. The helper activity was much higher in patients treated with IL-2 plus VO than IL-2 alone.

Adenocarcinoma↗